

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-137. (Cancelled)

138. (Currently Amended) A method for producing a polypeptide capable of stimulating an immune response against a molecule, the method comprising:

(a) identifying a molecule against which the stimulation of the immune response is desired, the molecule ~~selected from the group consisting of: a Group 5 allergen of a house mite of species *Blomia tropicalis* (Blo t 5) or a Group 2 allergen of a house mite of species *Dermatophagoides pteronyssinus* (Der p 2); and~~

(b) forming a fusion protein by joining the molecule as a first portion thereof with a second portion being an Fve polypeptide having a sequence shown as SEQ ID NO: [[1]] 6 and comprising a mutation selected from the group consisting of: a mutation from R to A at position 27 of that sequence (R27A) and a mutation from T to A at position 29 of that sequence (T29A).

Claims 139-172. (Cancelled)

173. (Previously Presented) The method of Claim 138, in which the first portion comprises a Group 2 allergen of a house mite of species *Dermatophagoides pteronyssinus* (Der p 2) and the second portion comprises an FveR27A polypeptide having a sequence shown as SEQ ID NO: 32.

174. (Previously Presented) The method of Claim 173, in which the polypeptide comprises a Der p 2-FveR27A fusion protein comprising a sequence shown as SEQ ID NO: 44.

175. (Previously Presented) The method of Claim 138, in which the first portion comprises a Group 2 allergen of a house mite of species *Dermatophagoides pteronyssinus* (Der p 2) and the second portion comprises a FveT29A polypeptide having a sequence shown as SEQ ID NO: 36.

176. **(Previously Presented)** The method of Claim 175, in which the polypeptide comprises a Der p 2-T29A fusion protein comprising a sequence shown as SEQ ID NO: 46.

177. **(Previously Presented)** The method of Claim 138, in which the polypeptide further comprises a glutathione S transferase (GST) moiety.

178. **(Previously Presented)** The method of Claim 138, which comprises joining a first nucleic acid sequence encoding the molecule against which the stimulation of the immune response is desired to a second nucleic acid sequence encoding the Fve polypeptide to form a construct.

179. **(Previously Presented)** The method of Claim 178, in which the first nucleic acid and the second nucleic acid are joined in an expression vector, and the fusion protein is expressed from the expression vector.